Stanford APBI Trial
Clinical Trial
Overview
Accelerated, partial breast irradiation (APBI) is a potentially important new way to incorporate radiotherapy in the treatment of women with breast cancer.
Currently, women with breast cancer who undergo a lumpectomy typically have 6 1/2 weeks of radiation to the entire affected breast after surgery. Accelerated, partial breast irradiation (APBI) changes this approach in two ways. It shortens the treatment time from 6 1/2 weeks to between 1 to 5 days, and reduces the treatment area from the entire breast to the area of the breast immediately around the lumpectomy site. This is the part of the breast where most cancers are likely to recur.
In many ways APBI is to current whole breast radiotherapy what a lumpectomy is to a mastectomy. The goal is to use a less invasive more focused treatment without compromising survival.
APBI has been used in limited trials in several hundred patients over the last 10 years. These trials show that in properly selected breast cancer patients APBI worked just as well as whole breast radiotherapy. In the initial studies, investigators relied on the placement of many catheters in the breast tissue (interstial brachytherapy). Newer techniques will hopefully provide the same good results but will deliver the radiation in faster and/or more convenient ways. This could increase interest in APBI and allow additional clinical trials that test the safety and effectiveness of the newer approaches. These newer approaches could increase quality of life for many women with breast cancer.
Investigators at Stanford University Medical Center are currently offering an IRB approved clinical trial that uses three new approaches for APBI. These three approaches are:
Intraoperative Radiotherapy (IORT) - 1 day
Intracavitary Brachytherapy (MammoSite) - 5 days
3-D Conformal/External Beam Radiotherapy - 5 days
The Stanford trial is led by Dr. Frederick Dirbas, Assistant Professor of Surgery, and by Dr. Donald Goffinet, Professor of Radiation Oncology. For further information about the trial please contact Janelle Maxwell or Triona Dolphin at (650) 498-7740.
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: HGS1036 + Paclitaxel + Carboplatin
- drug: HGS1036 + Cisplatin + Etoposide
- drug: HGS1036 + Docetaxel
Eligibility
Inclusion Criteria:
- Have a histological or cytological diagnosis of malignant solid neoplasm requiring
systemic chemotherapy.
- Age ≥18 years.
- ECOG performance status 0-1.
- Adequate organ function.
- Adequate hematological function.
- Have the ability to understand the requirements of the study, provide written informed
consent, and comply with the study protocol procedures.
- Consent to collection of previously obtained, archival biopsy or surgical specimens of
the currently treated malignancy when available.
Exclusion Criteria:
- Significant cardiac disease.
- Eye trauma or disease.
- Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months
prior to first dose of HGS1036.
- Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of
HGS1036.
- Major surgery within 4 weeks of the first dose of HGS1036.
- Prior organ or allogeneic stem cell transplant.
- Non-healing or chronic wounds.
- Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.
- Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of
the first dose of HGS1036.
- Active CNS involvement by primary or metastatic tumor.
- Documented active infection requiring the use of systemic antibiotics.
- Pregnancy or lactation.
- Known HIV-positive serology, AIDS, or an AIDS-related illness.
- Conditions likely to increase the potential for abdominal perforation or fistula
formation.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jennifer Vargas
650-723-0371
Not Recruiting
What's New
Stanford’s APBI trial has now been expanded to include women with ductal carcinoma in situ (DCIS). Please call 650-498-7740 for more information.